The earnings call highlighted significant strategic advancements in customer partnerships, pipeline progress, and operational efficiencies, suggesting a focus on long-term growth. However, the quarter experienced a decline in revenue and a net loss, influenced by specific non-recurring adjustments and increased SG&A expenses. Overall, the sentiment reflects cautious optimism, balancing growth initiatives with current financial challenges.

Company Guidance

During Lifecore's Fiscal 2025 Third Quarter Earnings Call, the company reiterated its financial guidance for the fiscal year, projecting revenues between $126.5 million and $130 million and an adjusted EBITDA ranging from $19 million to $21 million. The third quarter revenues were $35.2 million, a 2% decrease from the previous year, primarily due to a $1.5 million decline in CDMO revenues, offset by a $1 million increase in hyaluronic acid manufacturing revenues. The company reported a net loss of $14.8 million or $0.47 per diluted share, in contrast to a net income of $15.6 million or $0.42 per diluted share the previous year. Gross profit for the quarter was $9.8 million, down from $11.9 million, with a $2 million decline attributed to lower CDMO gross profit. Selling, general, and administrative expenses slightly increased to $10.1 million, with notable litigation expenses impacting the current period. Despite these challenges, Lifecore is focused on a 12% revenue CAGR and aims to improve EBITDA margins to over 25% in coming years, supported by strategic partnerships and new business ventures.

Strong Customer Engagement and Expansion

Lifecore signed multiple new agreements with both new and existing customers, including a significant partnership with a large multinational partner poised to deliver a significant inflection point in volume demand in 2027.

Pipeline Advancements Towards Commercialization

10 of Lifecore's late-stage pipeline programs are poised for potential FDA approval by 2028. Significant milestones were achieved, including a statement of work with a large multinational partner and a PPQ campaign commitment.

Operational Efficiencies and Cost Reductions

Lifecore has improved production efficiencies, reduced operational expenses, and eliminated numerous consulting relationships. Enhanced productivity in direct labor areas and improved fermentation processing efficiency were noted.

Positive Cash Flow from Operations

The company achieved positive cash flow from operations of approximately $2 million during the quarter, despite one-time non-recurring expenses.

Lifecore Biomedical (LFCR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LFCR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 03, 2025	2026 (Q1)	-0.32 / -	-0.53	―	―	―
Aug 07, 2025	2025 (Q4)	-0.10 / -0.06	-0.16	62.50% (+0.10)	―
Apr 03, 2025	2025 (Q3)	-0.15 / -0.47	0.4	-217.50% (-0.87)
Jan 02, 2025	2025 (Q2)	-0.29 / -0.25	0.39	-164.10% (-0.64)	―
Oct 04, 2024	2025 (Q1)	-0.49 / -0.53	-0.35	-51.43% (-0.18)	―
Aug 26, 2024	2024 (Q4)	-0.12 / -0.16	-1.19	86.55% (+1.03)	―
Apr 02, 2024	2024 (Q3)	-0.06 / -0.06	-1.33	95.49% (+1.27)	―	―
Jan 03, 2024	2024 (Q2)	-0.13 / -0.13	-0.42	69.05% (+0.29)	―	―
Oct 03, 2023	2024 (Q1)	- / -	―	―	―	―
Aug 31, 2023	2023 (Q4)	-0.39 / -0.35	-0.41	14.63% (+0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LFCR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$7.76	$7.24	-6.70%
Apr 03, 2025	$6.81	$5.29	-22.32%
Jan 02, 2025	$6.66	$7.62	+14.41%
Oct 04, 2024	$4.70	$5.38	+14.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lifecore Biomedical (LFCR) report earnings?

Lifecore Biomedical (LFCR) is schdueled to report earning on Oct 03, 2025, After Close (Confirmed).

What is Lifecore Biomedical (LFCR) earnings time?

Lifecore Biomedical (LFCR) earnings time is at Oct 03, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LFCR EPS forecast?

LFCR EPS forecast for the fiscal quarter 2026 (Q1) is -0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing